Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Bladder Cancer
- Anal Cancer
- Renal Cell Carcinoma
- Ovarian Cancer
- Biliary Tract Cancer
- Cervical Cancer
- Gastric Cancer
- Head and Neck Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Melanoma
- Skin Squamous Cell Carcinoma
- Merkel Cell Carcinoma
- Small Cell Lung Cancer
- Mesothelioma
- Triple -Negative Breast Cancer
- Non -Small Cell Lung Cancer
- Microsatellite Instability High
- Thymic Cancer
- Thyroid
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study will assess the safety and tolerability of SO-C101 administered as monotherapy and in combination with an anti-PD-1 antibody (pembrolizumab) in patients with selected relapsed/refractory advanced/metastatic solid tumors (renal cell carcinoma, non-small cell lung cancer, small-cell lung ca...
This study will assess the safety and tolerability of SO-C101 administered as monotherapy and in combination with an anti-PD-1 antibody (pembrolizumab) in patients with selected relapsed/refractory advanced/metastatic solid tumors (renal cell carcinoma, non-small cell lung cancer, small-cell lung cancer, bladder cancer, melanoma, Merkel-cell carcinoma, skin squamous-cell carcinoma, microsatellite instability high solid tumors, triple-negative breast cancer, mesothelioma, thyroid cancer, thymic cancer, cervical cancer, biliary track cancer, hepatocellular carcinoma, ovarian cancer, gastric cancer, head and neck squamous-cell carcinoma, and anal cancer).
Tracking Information
- NCT #
- NCT04234113
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon